XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 31, 2018
Oct. 31, 2017
Mar. 31, 2022
Mar. 31, 2021
Summary Of Significant Accounting Policies [Line Items]        
Increase in expected cost percentage     2.00%  
Reduced revenue     $ 1,800,000  
Deferred revenue     486,700,000  
AbbVie Biotechnology Limited        
Summary Of Significant Accounting Policies [Line Items]        
Upfront payments   $ 205,000,000    
Upfront payment received $ 200,000,000 5,000,000    
Exclusive option rights exercised for each program   250,000,000    
Collaboration revenue     3,300,000 $ 4,100,000
Deferred revenue     114,100,000 $ 128,200,000
AbbVie Biotechnology Limited | Maximum        
Summary Of Significant Accounting Policies [Line Items]        
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval   $ 242,800,000    
Innovent        
Summary Of Significant Accounting Policies [Line Items]        
Collaboration revenue     0  
Development milestone     11,500,000  
Sales milestone     $ 112,500,000